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Abstract
Regarding  to  the  World  Health  Organization’s  2011  published  list  of the  top  ten 
causes of death worldwide, HIV/ AIDS is still listed as the 6 th most frequent reason for 
fatality.  Previous  analyses  with  a  Yeast  two-hybrid  (Y2H)  screen  identified  the 
tetraspanin CD63 as an interaction partner of the HIV-1 protein gp41 and unveiled 
some  highly  conserved  cysteines  in  its  Large  Extracellular  Loop  as  involved 
interaction sites between those two proteins. The aim of this study was to investigate 
the role of the CD63's Large extracellular loop on HIV-1 entry and cell-to-cell transfer.  
For this purpose several expression plasmids encoding for recombinant variants of 
the Large Extracellular Loop were generated. One did express the CD63 without the 
whole loop and four contained in each case a different mutation of one or two of the 
six cysteines.
Studies  of  the recombinant  protein's  expression with  the confocal  laser  scanning 
microscope showed that only one cystein mutant was completely expressed like the 
wild type CD63.  Two cysteine mutants were not expressed consistently throughout 
the HEK293T cells and one appeared to be not expressed on the surface of the 
plasma membrane. Surprisingly, recombinant protein without the Large Extracellular 
Loop  was  expressed  predominantly  on  the  surface  of  the  plasma  membrane. 
Subsequently some foreign protein sequences were introduced instead of this loop. It 
could be confirmed that these foreign proteins can be added without affecting the 
overall  efficiency of  the proteins integration into  the cell  membrane. Furthermore, 
introducing certain  foreign proteins does neither affect  the protein  folding nor  the 
protein orientation.
Once this membrane transport system is established, it could be used in the field of 
immunisation  studies,  antibody  production  or  other  immunological  experiments, 
where the exposure of certain proteins on the cell surface of mammalian cells is of  
interest.  Unfortunately,  due to strict  time constraints experiments investigating the 
recombinant protein's influence on HIV-1 entry and cell-to-cell transfer could not be 
performed.
The results gathered during the course of this research revealed some promise of 
usefulness. However,  in regards to the CD63's overall  influence on cell  free virus 
infectivity  and  cell-to-cell  transfer  in  T  lymphocytes,  it  would  appear  the  current 
understanding is that no significant influence can be shown. This would suggest that, 
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AIDS Acquired Immune Deficiency Syndrome
bp Base pairs
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GFP Green Fluorescent Protein
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HEK293T Human Embryonal Kidney cells
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HeLa Cervical cancer cell line taken from Henrietta Lacks
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HIV-1 Human Immunodeficiency Virus  type 1




LB-Medium Lysogeny Broth Medium
LEL Large Extracellular Loop




PBS Phosphate Buffered Saline
pCMV Expression vector: Cytomegalovirus plasmid
PCR Polymerase chain reaction
pfu Plaque-forming units
Pol Polymerase, enzymatic activities
RNA Ribonucleic acid
rpm Rounds per minute
RPMI Roswell Park Memorial Institute Medium
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEL Small Extracellular Loop
SEM-cLSM
Scanning Electron Microscope – confocal Laser Scanning 
Microscopy
SOC-Medium Super Optimal Broth Medium + 20mM Glucose
TAE Tris-acetate-EDTA buffer
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VS Virological synapse





The  Acquired  Immune  Deficiency  Syndrome  (AIDS)  is  a  disease  caused  by  the 
Human Immunodeficiency Virus (HIV). The World Health Organization (WHO)’s 2011 
published list of the top ten causes of death worldwide, still lists HIV/ AIDS as the 6th 
most frequent reason for fatality.  After more than 20 years of research and great 
advances in  the  antiretroviral  therapy,  it  remains  one of  the  world’s  major  public 
health issues, one that has claimed more than 36 million lives to date [1]. The WHO 
further estimates around 35.2 million people living with HIV worldwide, while just one 
quarter of those are having access to the vital antiretroviral medication for therapy 
[2]. Although this therapy mostly decreases the virus load in the blood to under a 
detectable limit, the persistence of HIV in some special human immune cells remains 
a determining  factor  preventing  HIV from being completely  eradicated.  Despite  a 
consistently increasing knowledge of this lentivirus, mechanisms of the cell entry and 
that persistence are not yet fully understood. HIV-1 remains particularly prevalent 
within macrophages and T-lymphocytes, due to their comparably long life span of up 
to ten years. 
Furthermore, it has been well documented that the virus can be transferred efficiently  
from cell to cell via structures called Virological Synapses (VS), which appear to be 
special adhesion sites between infected and uninfected cells [3]. Chen et al. could 
show  that  HIV-1  transferred  that  way  is,  in  addition,  neutralization-resistant  [4]. 
Therefore, the understanding of this particular spreading mode becomes even more 
vital. Continuing studies showed that this transport system and the formation of the 
synapse is mainly driven by Env-CD4 interactions [5], [4], while others documented 
the  involvement  of  tetraspanins  [3],  [6].  Earlier  analyses with  a  Yeast  two-hybrid 
(Y2H) screen identified the tetraspanin CD63 as an interaction partner of the HIV-1 
protein  gp41  and  showed  that  some  highly  conserved  cysteines  in  its  Large 
Extracellular Loop (LEL) are important for the binding between those two proteins [7]. 
To  analyse  the  role  of  the  LEL  in  this  interaction,  several  expression  plasmids 
encoding for recombinant variants of the Large Extracellular Loop were generated. 
One did  express the  CD63 without  this  loop and four  contained in  each case a 
different mutation of one or two of the six cysteines. The purpose of my study was to  
investigate the influence of the CD63-LEL on HIV-1 entry and cell-to-cell transfer.
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1.1. The Human Immunodeficiency Virus (HIV)
HIV is a retrovirus from the subgroup of lentiviruses, with a size of approximately 100 
nm. The difference between the genomes of the AIDS causing subtype HIV-1 and the 
subtype HIV-2 is 40%. An envelope surrounds the capsid that is characteristical for 
the retrovirus and consists of the p24 capsid protein. Inside of the capsid there are 
two viral, single stranded RNA copies that are complexed with the p7-protein, but not 
covalently linked to each other. The viral glycoproteins, such as gp120 and gp41, part 
of the functionally active complex that is involved in the virus budding, is anchored as 
transmembrane protein within the envelope. The virus further contains the enzymes 
reverse  transcriptase,  integrase  and  protease.  The  around  7000  nucleotide  long 
retrovirus genome encodes for group-specific antigen (gag), polymerase (Pol) and 
enzymatic activity and for envelope(Env) and glycoprotein gene products. It further 
contains  additional  protein  encoding  gene  regions  for  regulatory  and  accessory 
proteins [8].
HIV can be transferred from one human to another, either via unprotected sexual 
intercourse,  via  transfusions  of  infected  blood  or  while  injecting  drugs  with  used 
needles. Summed up, it can be transmitted via specific infectious body fluids. Hence, 
it can further be transmitted from a mother to her baby during the birth process or 
while breast feeding. 
As the HIV genome itself only encodes 15 proteins, it must exploit multiple functions 
and proteins of the host cell for a productive infection. More than 250 host factors are 
required by HIV-1 [9]. The virus entry into its host cell usually consists of three steps: 
(i) the envelope gp120 protein of the virion attaches to the CD4+ host cell surface, (ii) 
the  now  conformationally  altered  gp120  interplays  with  CCR5  and  CXR4  co-
receptors and, finally,  (iii)  the envelope gp41-protein mediates the fusion with the 
target cell [10]. 
Nevertheless, there has been evidence that the infection of certain cell-types occurs 
independently of these factors [8]. Once the RNA enters into the cell plasma of the 
host cell, the reverse transcriptase starts to transform it  into a double stranded DNA 
molecule via several steps. Due to this enzyme’s lack of a proof reading activity, the 
statistical  mutation  rate  occurs  to  be  very  high.  The  following  transport  of  this 
molecule into the nucleus is driven by further proteins and enzymes. Once the viral  
DNA has been inserted into the nucleus, the integrase incorporates it into the DNA 
genome of the host cell.  This makes HIV the only known  virus that is enabled to 
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infect cells in the stationary phase and not just during mitosis. Once this DNA starts 
getting expressed and an mRNA is built, the viral proteins get transcribed and a new 
viral RNA is built as well. These viral components then bind together and bud to a 
new virion with all  its glycoproteins at the host cell  membrane. After a process of 
maturation, the particles can infect a new cell and the replication cycle can start over 
again [8]. 
As HIV integrates into the host DNA, it can remain in a transcriptionally inactive or  
latent form for extended periods [11]. During infection, HIV remains and concentrates 
in some reservoirs in its host. Organelles within macrophages were described in an 
earlier study as preferential sites for virus accumulation in macrophages [12]. Current 
research provided that not just macrophages, but also T cells and dendritic cells are 
main reservoirs of HIV, even under retroviral therapy [13]. Due to the macrophages 
resistance to the process of apoptosis, they are persistent cellular reservoirs of HIV. 
Recent data showed that the human lung serves as an anatomical reservoir, as a 
result of the close proximity of a large number of immune cells, which provide ideal 
conditions for a cell-to-cell spread of HIV [14].
1.2. The Virological Synapse
The VS has not yet been investigated very well. First studies suggest that it shares 
some characteristics with the better known Immunological Synapse (IS), which forms 
between antigen presenting cells and T lymphocytes [15]. It is also comparable to the 
neural synapse, as in case of the VS the effector cell does not fuse with the target 
cell.  This  seems illogical  in  the  beginning  due  to  the  fact  that  effector  cells  are 
enriched with Env and Gag at their surface while the target cells are enriched with 
CD4  and  CXR4  co-receptors.  The  tetraspanin  CD63  and  HIV-1  have  been  co-
localised at this structure during live cell imaging [7]. Further, the tetraspanins CD9 
and  CD81  seem  to  prevent  the  fusion  process  through  their  presence  at  the 
virological postsynapse and presynapse [16].
1.3. Structure of tetraspanins
Tetraspanins  are  a  33-member  super  family  of  four-span  transmembrane  glyco-
proteins with a very characteristic structure, from which their name is derived. These 
proteins, also known as TM-4's, pass the cell membrane four times while building two 
typical  extracellular  regions,  the  Small  Extracellular  Loop  (SEL)  and  the  Large 
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Extracellular Loop (LEL). They further contain short cytoplasmic N- and C-termini as 
well as a shorter inner loop structure (Fig.1) that separates the SEL from the LEL 
[16]. An interspecies key feature that defines the tetraspanins, is at least four and up 
to  six  cysteines  within  the  LEL,  where  one  cysteine  couple  is  part  of  a  highly 
conserved -CCG- motif. Due to the typically formed disulphide bonds a sub-loop is 
created,  which  represents  another  defining  feature.  This  explains  the  LEL 
organization in two structural subdomains. The first one appears to have a primarily 
structurally conserved fold.  The second one begins after the -CCG- motif,  and is 
extremely variable in its size, secondary fold, and its structure. 
Fig.1:  The tetraspanin model  shows the typical  protein  structure.  The four transmembrane regions (TM) are 
spanning the cell membrane, the Small Extracellular Loop (SEL), a small intracellular loop that separates the SEL 
from the  LEL,  and the  Large  Extracellular  Loop  (LEL)  with  six  cysteines,  as  found  in  CD63,  with  bonding 
disulphide bridges . (own illustration)
However,  the  disulphide  bridges  remain  the  key  organising  factor  [17]. 
Simultaneously this protein structure is hyper-variable within the tetraspanin family 
and  homologous  between  different  species  [18].  Some  tetraspanins  contain  an 
additional  cysteine  couple,  such  as  the  tetraspanin  CD63.  Therefore,  they  have 
altogether six cysteines within the LEL. Based on the amino acid sequence of the 
LEL, Seigneuret et al. subdivided the tetraspanin family into four subgroups. Over the 
past few years studies revealed the presence of tetraspanin-enriched microdomains 
(TEMs)  within  the  lipid  bilayer.  These  are  specialised  regions  on  the  membrane 
surface  with  a  higher  density  of  tetraspanins.  For  example  Nydegger  et  al. 
discovered CD9, CD63, CD81 and CD82 containing TEMs on the surface of fixed 
HeLa cells [19]. 
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This phenomenon has also been shown in live cells, where these proteins have been 
found to locally concentrate and work as “interaction platforms” [20].
1.4. Functions of tetraspanins
Phylogenetic analysis, as done by Huang et al. in 2005, revealed that tetraspanins 
seem  to  play  an  important  role  in  the  transition  from  unicellular  to  multicellular 
organisms.  It  has  been  shown  that  these  proteins  have  undergone  an  intense 
evolution and the different cysteine patterns of the LEL have been introduced as an 
important classification factor. Tetraspanins are not only expressed in metazoans but 
also in protozoan, amoebae, fungi and plants. Drosophila melanogaster, for example, 
has 36 tetraspanins,  Caenorhabditis elegans on the other hand only has 20 [21]. 
However,  Meacker  et  al.  further  documented  that  tetraspanins  are  distributed  in 
almost all cell types and that each cell type expresses various and different kinds as 
well as different amounts of tetraspanins. Interestingly, some tetraspanins, such as 
CD9, CD63, CD81 and CD82, can be found in almost every tissue, whereas some 
others appear only in special tissues, like CD37 in B-cells [22]. Generally, it can be 
said that these molecules play a role in cell-cell and cell-matrix interactions, which 
include  processes  such  as  cell  adhesion,  cell  migration,  signal  transduction, 
activation, proliferation and differentiation [23].
Each  of  these  group  members  can  bind  with  special  protein  partners  such  as 
integrins,  co-receptor  molecules,  major  histocompatibility  complex  antigens  and 
cytoplasmic kinases [24] via the LEL as the main protein binding domain [21]. Based 
on  the  named  subgroup  system  it  has  been  found  that  members  of  the  same 
subgroup  and  therefore  with  similar  structural  LEL  characteristics  can  partially 
assume each other’s functions [16]. Therefore, just a few knock-out experiments lead 
to dramatic phenotypes, for example a CD9 knock-out in mice resulted in a loss of  
fertility caused by an inability of the oocytes to fuse with the sperm, or in the case of 
peripherin  (CD22)  knock-out  mice,  which  resulted  in a  retinal  degeneration  [25]. 
Tetraspanins  furthermore  play  regulative  roles  in  cancer  development.  CD9 
monoclonal  antibodies,  for  example,  can  inhibit  the  transendothelial  migration  of 
melanoma cells  [26].  They also have been found to  both promote  and suppress 
development of metastasis [27].
Last but not least, tetraspanins have been shown to be important interaction partners 
of different viruses. CD81 for instance is an essential binding partner for the HCV 
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(Hepatitis C virus) envelope protein E2 [28]. Another research [29] revealed that the 
CD82 interaction with the membrane glycoprotein of the Human T-cell Leukaemia 
Virus type 1 (HTLV-1) inhibits cell-to-cell fusion and virus transmission. And finally, 
tetraspanins influence the assembly,  budding, entry and cell-to-cell  transfer of  the 
Human Immunodeficiency Virus type 1 (HIV-1).
1.5. CD63 and HIV-1
Some of the earlier studies that investigated the incorporation of proteins from host 
cells into HIV-1 particles revealed CD63 to be one of them [30, 31]. Soon after that it 
was  established  that  HIV-1  exits  at  tetraspanin  enriched  segments  of  the  cell 
membrane.  Another  early  research  found  that  the  non-random process  of  CD63 
incorporation  into  virions  is  specifically  found  when  they  are  released  from  T 
lymphocytes [32]. Those previous findings were strengthened about ten years later, 
when several studies showed that HIV-1 exits on TEMs that are enriched with CD9, 
CD63,  CD81  and  CD82  in  epithelial  cells,  T  lymphocytes,  macrophages,  and 
dendritic cells [33-37]. 
It  remained  unclear,  though,  whether  tetraspanins  play  a  functional  role  in  the 
budding process itself. Krementsov et al. found that although the treatment of virus 
producing HeLa cells with an anti-CD9 antibody reduced the virus release [38], the 
knockdown of CD9, CD63 and CD81 had no effect on the rate of HIV-1 release from 
these cells [3]. Their studies further revealed that tetraspanins have an impact on the 
infectivity of released virus particles and the cell-to-cell  transmission. Interestingly, 
the overexpression of CD63 in co-transfected HeLa cells decreased the infectivity of 
cell-free  virus  dramatically  and  inhibited,  just  like  the  CD9,  but  not  the  CD81 
overexpression,  cell-to-cell  transmission  of  HIV-1.  The  tetraspanin  knockdown, 
contrary to expectations, had no effect on the cell-free infectivity and only the CD81 
knockdown enhanced cell-to-cell transmission of HIV-1.
Further they provided evidence that HIV-1 can modulate the tetraspanin level in virus 
producing  cells  to  maximize  its  efficiency.  There  was  a  downregulation  of  all  
tetraspanins in newly infected Jurkat T lymphocytes, whereas there was no such 
downregulation  to  be  found  in  infected  HeLa  cells.  Finally,  despite  this  down-
regulating effect, a tetraspanin concentration was still  detectable at the Virological 
Synapse [3]. The scientists involved in this study therefore concluded: “Altogether,  
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currently  available  evidence  suggests  that  tetraspanins  do  not  generally  act  as 
budding co-factors for HIV-1” [16].
Therefore  on  the  one  hand,  findings  demonstrated  that  the  treatment  of 
macrophages and T lymphocytes with an anti-CD63 antibody inhibited the infection of 
these cells up to a level of 50%, but only if they were infected with a R5 tropic HIV-1 
strain. No such effect was shown for cells infected with X4 tropic strains of HIV-1 [39]. 
On the other hand,  it  could be shown that  recombinant  CD63 LELs also have a 
specifically inhibitory effect on macrophage infection, but  contrary to the antibody 
test, also on the X4-tropic virus [40]. The viral attachment and cell-cell fusion were 
not  affected  by  CD63  silencing,  but  the  CD63-depleted  macrophages  repeatedly 
showed an effect, this time a significant decrease in the initiation and completion of  
the  reverse  transcription  of  the  virus  [41].  This  study also  revealed that  a  down 
regulation of CD63 inhibits the p24 production, a late protein of the HIV replication 
cycle. Li et al.'s findings suggest an early post entry role for CD63, either prior to or at 
the step of reverse transcription.
1.6. The aim of this study
The aim of this study is to determine whether different mutations of the CD63-LEL 
have an effect on several steps of the CD63 development and HIV infection. First of  
all, it was of interest, whether a depletion of the complete LEL, or one of the point 
mutations of the LEL's cysteines would prevent the protein from being integrated into 
the cell membrane at all. As far as it is known, no research has unveiled this process 
to  date.  This  research  therefore  started  with  the  generation  of  recombinant 
expression  plasmids.  The  used  cDNA originates  from  a  Y2H library.  The  pCMV 
expression vector was used to  overexpress the recombinant proteins in  eukaryotic 
cells. The second part of this research deals with the influence of these recombinant  
LELs on HIV-1 entry and the cell-to-cell transmission. The main focus was the LEL 
because of its importance as a protein binding region. Four different HIV-1 strains 
were used for the infection experiments. Three of them, as well as all  constructs, 
were tagged with fluorescent proteins, which made it possible to easily localise them 
with the confocal laser scanning microscope.
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2. Material and Methods
2.1. Material
2.1.1. PCR- Components
Table 1: All used PCR components and their manufacturers
PCR- Components Manufacturer
10x  PfuUltra™ II Reaction Buffer Agilent Technologies
10x FastDigest Buffer FD ThermoScientific
5 x T4 DNA Ligase Buffer NewEngland BioLabs®
Abi BigDye 3.1. Terminator Chemie
Deoxycytidine nucleoside triphosphates 
(dNTPs)
Agilent Technologies
NEBuffer 2,NEBuffer 3, NEBuffer 4 NewEngland BioLabs®
PfuUltra™ II Fusion HS DNA Polymerase Agilent Technologies
Restriction enzyme ApaI NewEngland BioLabs® + FD ThermoScientific
Restriction enzyme BamHI NewEngland BioLabs® + FD ThermoScientific
Restriction enzyme EcoRI NewEngland BioLabs® + FD ThermoScientific
Restriction enzyme EcoRV NewEngland BioLabs® + FD ThermoScientific
Restriction enzyme HindIII NewEngland BioLabs® + FD ThermoScientific
Restriction enzyme MfeI FD ThermoScientific
Restriction enzyme PstI NewEngland BioLabs® + FD ThermoScientific
Restriction enzyme XhoI NewEngland BioLabs® + FD ThermoScientific
T4 DNA Ligase NewEngland BioLabs®
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2.1.2.  Primer
Table 2: All primers used with their abbreviation and sequence, all primers were ordered from 
Sigma Aldrich
Primer Sequence in 5'- 3' direction
C145A,C146A for GCAGGCAGATTTTAAGGCTGCTGGGGCTGCTAACTACACAGATTG
C145A,C146A rev CAATCTGTGTAGTTAGCAGCCCCAGCAGCCTTAAAATCTGCCTGC








4A3/TM4 for  TTTTTGATATCGGAGGAGGAGGAAA AAATGTGCTGG
4A3/TM4  rev TTTTTTAAGCTTCATCACCTC GTAGCC ACTTCT






2.1.3. Buffer and Media
Table 3: All used Buffer stocks and media with their ingredients
Buffer/ Media Ingredients
1 x HBS- Buffer 5 mM KCl; 137 M NaCl; 0,7 mM Na2HPO4; 7,5 mM D-glucose; 21 mM 
HEPES
2YT- Medium 1,6% Bacto tryptone; 1% Bacto yeast extract; 0,5% NaCl
50x TAE - Buffer 2 M Tris, 1 M glacial acetic acid; 100 ml 0,5 M EDTA
DMEM-complete 500 ml DMEM, 2 mM L-glutamine, 100 IU/ml penicillin, 100 µg /ml 
streptomycin, 10% BSA
DMEM-serum free 500 ml DMEM, 2 mM L-glutamine,  100 IU/ml penicillin, 100 µg /ml 
streptomycin
LB- Medium 1% Bacto tryptone; 0,5% Bacto yeast extract; 1% NaCl
PBS- Buffer 2,7 mM KCl; 137 M NaCl; 1,5 mM KH2PO4; 8,1 mM Na2HPO4
RPMI- complete 500 ml RPMI, 2 mM L-glutamine, 100 IU/ml penicillin, 100 µg /ml 
streptomycin, 10% BSA




25 mM Tris, 192 mM glycine, 0,1% (w/v) SDS (pH 8,3)
Laemli buffer 2x 50 mM Tris-HCl pH 6,8; 2% SDS; 10% glycerol; 1% β-
mercaptoethanole; 12,5 mM EDTA; 0,02% bromophenol blue
SOC- Medium 2% Bacto tryptone; 0,5% Bacto yeast extract; 0,05% NaCl; 2,5 mM 
Kcl; 10 mM MgCl2; 20 mM Glucose
TB- Medium 1,2% Bacto tryptone; 2,4% Bacto yeast extract; 0,5% Glycerol; 1M 
KHPO4
TFB I dH2O depending on volume; 5 % (v/v) Glycerine; 100 mM RbCl ; 30 
mM Kaliumacetate; 10 mM CaCl2; pH 5,8; 50 mM MnCl2
TFB II dH2O depending on volume; 15 % Glycerine; 10 mM RbCl; 10 mM 
MOPS; 75 mM CaCl2; pH 6,8;
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2.1.4. Other chemicals
Table 4: All other chemicals that were used including their respective manufacturers
Name Manufacturer
6x Orange DNA Loading Dye Thermo Fisher Scientific Inc.
Agarose Carl Roth GmbH + Co. KG
Ampicillin sodium salt Carl Roth GmbH + Co. KG
Benzonase® Nuclease Sigma-Aldrich® Chemie GmbH
Bovine Serum Albumine (BSA) NewEngland BioLabs® GmbH
CPRG Sigma-Aldrich® Chemie GmbH
Dimethyl sulfoxide (DMSO) Sigma-Aldrich® Chemie GmbH
Ethidium bromide Sigma-Aldrich® Chemie GmbH
Kanamycin sodium salt Carl Roth GmbH + Co. KG
Metafectene®PRO Biontex Laboratories GmbH
O´GeneRuler™ DNA Ladder Mix Thermo Fisher Scientific Inc.
Penicillin/Streptomycin Biochrom AG Berlin
Pierce ECL Western blotting substrate Thermo Fisher Scientific Inc.
SDS Sigma-Aldrich® Chemie GmbH
Triton X-100 Carl Roth GmbH + Co. KG -
Trypsine-EDTA Biochrom AG Berlin
β-Mercaptoethanol Sigma-Aldrich® Chemie GmbH
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2.1.5. Biological material
Table 5: All biological components used; all strains were already existing at the laboratory
Abbreviation Description/ manufacturer
ER 9295 Transgene E.coli for transfection that is dam-/dcm- (Nous Bio)
g-anti-FLAG goat anti-FLAG antibody (first antibody) - (Dako)
g-anti-HRP goat-anti-HRP konjugate (second antibody) - (Dako)
HEK293T Human  Embryonic  Kidney  293T  cells  (National  Institute  of 
Health)
HIV-iGFP Vector  carrying  HIV  proviral  genome  with  an  internal  Green 
Fluorescent Protein (GFP); R5 tropic (Chen)
HIV-IRES R5 Vector carrying HIV proviral genome with an external GFP; R5 
tropic (Kirchhoff, Ulm)
HIV-IRES X4 Vector carrying HIV proviral genome with an external GFP; X4 
tropic (Kirchhoff, Ulm)
Jurkat cells Human T-lymphocyte cells - acute T-cell leukaemia (S. Norley)
m-anti-mCherry mouse-anti-mCherry antibody (first antibody) - (Abcum)
m-anti-HRP Mouse-anti-HRP antibody (second antibody) - (Abcum)
pCMV/CD63 Expression  vector  of  the  Cytomegalie  virus  where  the  CD63 
sequence is introduced at the multiple cloning site (Ivanusic)
pNL4-3 Vector carrying HIV proviral genome; X4 tropic (National Institute 
of Health)
r-anti-GFP rabbit-anti-GFP antibody (Abcam, ab6556)
anti-human-immunogold Anti-human antibody with 10 nm gold particles (Dako)
anti-rabbit-immunogold Anti-rabbit antibody with 10 nm gold particles (Dako)
r-anti-HRP rabbit-anti-HRP conjugate (Dako) (second antibody)
TZM-bl Transgene version of Human cervical cancer cell line taken from 
Henrietta  Lacks  (HeLa  cells)  –  having  CD4  and  chemokine 
receptors
XL-1 blue Transgene  Escherichia  coli  (E.coli) strain  for  transfection 
(Stratagene)
XL-10 gold Transgene E.coli strain for transfection (Stratagene)
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2.1.6. Kits
Table 6: All kits used and their respective  manufacturers
Name of the kit Manufacturer
EndoFree® Plasmid Maxi Kit QIAGEN N.V.
Plasmid Midi Kit QIAGEN N.V.
Spin DNA Extraction Kit Invisorb® Stratec molecular GmbH
Spin Plasmid Mini Two Kits Invisorb® Stratec molecular GmbH
2.1.7. Laboratory apparatus
Table 7: All laboratory apparatus used and their respective manufacturers
Apparatus name Manufacturer
BioPhotometer 8,5 mm Eppendorf AG Hamburg, Germany
Centrifuge 5804R Eppendorf AG Hamburg, Germany
Centrifuge 5810 R Eppendorf AG Hamburg, Germany
ChemoCam Imager 3.2 Intas Science Imaging Instruments GmbH, Germany
Classic Series C24 Incubator 
shaker
Eppendorf New Brunswick Scientific AG Hamburg, 
Germany
Confocal laser scanning 
microscope Zeiss LSM 780
Carl Zeiss AG Germany
Ecotron shaker INFORS HAT Germany
Megafuge 1.0R Hereaus Holding GmbH, Germany
Mini Spin Centrifuge Eppendorf AG Hamburg, Germany
Spektrophotometer ND-1000 NanoDrop® ThermoScientific Germany
Thermocycler vapo.protect 
Mastercycler pros
Eppendorf AG Hamburg, Germany
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2.2. Methods
2.2.1. Preparation of antibiotic containing agar plates
For the preparation of the plates, 7 g of agar were dissolved in 500 ml LB-Medium. 
The mixture was warmed until it started boiling and the agar was melted completely.  
After  cooling  the  solution  down  to  a  temperature  of  60°C,  either  100  µg/ml  of 
Ampicillin or 40 µg/ml of  Kanamycin, was added and everything  was then mixed 
carefully and thoroughly. Under sterile conditions, the LB-agar was poured into the 
petri dishes. Until usage, the dishes were stored at 4°C.
2.2.2. Preparation of 1% agarose gels
The gel electrophoresis required agarose gels, which were mixed from 50 ml 1x TAE-
buffer and 0,5 g of agarose. The mixture was heated in the microwave until it started 
boiling and the solution became clear.  After  allowing the solution to  cool down to 
40°C  5  µl  of  Ethidium  bromide  (10  mg/ml)  were  added.  Everything  was  mixed 
thoroughly and then poured into  the casting tray with  a comb for  the wells.  The 
hardened gel was then placed into a gel electrophoresis apparatus that was filled 
with 1x TAE-buffer.
2.2.3. Preparation and transformation of competent bacteria cells
2.2.3.1. Preparation of chemically competent cells
Cells were grown in each 50 ml of Terrific-Broth Medium (TB-Medium), which  had 
been inoculated with 100 µl of XL-1 blue or XL-10 gold  E.coli strains,  which was 
stored at -80°C. The mixture was incubated at 37°C overnight. The next day 200 ml 
Lysogeny-Broth (LB) Medium was inoculated with 1 ml of these overnight bacteria 
cultures. The bacteria were growing up to an OD600 of 0,4 – 0,7 at 37°C and 200 
rounds  per  minute  (rpm)  in  the  incubator  shaker.  Afterwards the  cells  were 
centrifuged (4°C; 3500 rpm; 5 minutes) and resuspended in 60 ml TFB I, which was 
cooled down on ice. The suspension was left on ice for 90 minutes and centrifuged 
again (4°C; 3500 rpm; 5 minutes) after which, the pellet was resuspended in 8 ml 
TFB II solution. 100 µl aliquots were prepared from the resulting bacteria mixture and 
flash frozen in liquid nitrogen before they were stored at -80°C until usage.
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2.2.3.2. Transformation of chemically competent cells
The chemically competent  E. coli aliquots were slowly defrosted on ice and then 
mixed with 1 to 5 ng of plasmid-DNA. The tubes were continuously stored on ice and 
incubated for 30 minutes, before the bacteria plasmid mixture was heat shocked for 
90 seconds at 42°C and once again incubated on ice for 5 minutes. After adding 150 
µl of Terrific Broth (TB) Medium the suspension was stored at 37°C for another 30 
minutes and then plated on Kanamycin containing agar plates. These petri dishes 
were left in the incubator (37°C) overnight until single colonies became visible.
2.2.4. Plasmid amplification
After  successful  transformation,  the single colonies were transferred under  sterile 
conditions into a 100 ml Erlenmeyer flask filled with 20 ml Kanamycin containing TB-
Medium (40 µg/ml). The mixture was incubated in a shaker for at least six hours at 
37°C and 200 rpm. There were at least two mutants picked and amplified from each 
successful transformation cycle. Once a good number of bacteria had grown, they 
were  miniprepped  to  harvest  the  plasmid-DNA.  The  DNA  concentration  was 
measured  using a Nanodrop spectro-photometer at a wave-length of 260 nm.
2.2.5. Site-directed mutagenesis
A two  primer  mutagenesis-PCR was  used  to  introduce  the  mutations.  Using  an 
already  existing  pCMV/CD63  vector,  altogether  four  cystein  mutations  were 
generated,  two double cystein  mutations (C145A,C146A;  C169A,C170A)  and two 
single cystein mutations (C177A; C191A). Primers were used as shown in table 2 
together  with  the  PfuUltra™  II  Fusion  HS  DNA Polymerase  in  a  ratio  of  1:25, 
PfuUltra™ II Fusion HS DNA Reaction Buffer and 40 mM dNTPs. The total reaction 
volume was 20 µl  for  each mutation.  The initial  solutions  were  then running the 
following temperature programme in a thermocycler:
-94°C 2 min
-94°C 45 s






From each batch 10 µl were used for the transformation of the chemically competent  
cells. Each mutagenesis was checked by Sanger sequencing. When the mutation 
was confirmed,  a  new  overnight  culture  was  grown  in  200  ml  of  Kanamycin 
containing TB-Medium (INFORS HAT Ecotron shaker, 37°C, 200 rpm) by inoculating 
it with 10 µl of a glycerine culture (stored at -20°C). The following day the plasmid-
DNA was extracted by using the Qiagen Plasmid Midi Kit, which was used according 
to the manufacturer’s specifications. Then once again, the mutations were checked 
by Sanger Sequencing (Abi BigDye).
2.2.6. Cloning
To prepare the CD63-ΔLEL (CD63 without  the LEL) cloning the modified primers 
4A3/TM1-3  for,  4A3/TM1-3  rev,  4A3/TM4  for,  4A3/TM4  rev  (table  2)  and  the 
pCMV/CD63 vector as the  template were used to amplify the fragments that were 
introduced  later.  A mixture  consisting  of  the  vector,  primer,  dNTPs,  PfuUltra™  II 
Fusion HS DNA Polymerase and  PfuUltra™ II Fusion HS DNA Reaction buffer ran 
through the following temperature programme in the thermocycler:
-95°C 5 min
-94°C 30 s




For checking purposes of the vector and the amplified fragments an agarose gel  
electrophoresis  was  used.  To  that  end  a  1%  agarose  gel  was  loaded  with   O
´GeneRuler™ DNA Ladder Mix and the samples  were  mixed with 6x Orange DNA 
Loading Dye. The gel was then placed into a gel electrophoresis apparatus that was 
filled with 1x TAE-buffer, and was then run for 30 minutes at a voltage of 90 V. The 
bands were  visualized with  UV light  in  the  ChemoCam and then  cut  out  with  a 
scalpel. The fragment containing gel was cleaned up with the Spin DNA extraction kit 
that was used according to the manufacturer’s specifications.
After a renewed measure of the DNA concentration through spectro-photometer, the 
vector and the fragments were digested with restriction enzymes. First the TM1-3 
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fragment and the empty pCMV vector were digested with BamHI and PstI restriction 
enzymes (NewEngland BioLabs®) for at least 5 hours. Then once again the DNA 
was run in   an agarose gel electrophoresis,  followed by another cleaning up and 
concentration measurement of the vector and the fragments.
The restricted and purified pCMV vectors were mixed with the TM1-3 fragments (1:5 
ratio), 5x T4 DNA ligase buffer, and T4 DNA ligase. The solution was ligated for 30 
minutes at 22°C, 30 minutes at 20°C and 60 minutes at 16°C. Following this, the 
ligated plasmids were transformed into the chemically competent cells as described 
and then amplified. The extracted DNA ran through another cycle of restriction digest 
with the same restriction enzymes. For this control digest, the DNA was restricted 
with  FastDigest  restriction  enzymes  from  ThermoScientific  for  30  minutes.  This 
control  was  resolved  by  agarose  gel  electrophoresis  as  before,  observed  for 
characteristic  restriction  fragment  pattern  under  UV  transillumination  and  then 
compared with the undigested control. If a 5000 bp fragment and a 335 bp fragment 
became visible, the cloning was successful.
The  pCMV/TM1-3  plasmid,  as  well  as  the  TM4  insert,  was  digested  with  the 
restriction enzymes EcoRV and HindIII (NewEngland BioLabs®) for at least 5 hours 
and then, as described, resolved by agarose gel electrophoresis. The DNA was once 
again extracted from the gel and ligated with a 1:5 plasmid-insert-ratio. Once the 
transformation was successful,  the clones were amplified and digested again with 
EcoRV  and  HindIII  (ThermoScientific)  to  control  the  ligation.  If  the  following  gel 
electrophoresis showed a 5000 bp and a 130 bp band, the cloning of the second 
insert was successful.
Subsequent  to  the cloning and the mutagenesis,  all  five constructs  pCMV/CD63-
C145A,C146A,  pCMV/CD63-C169A,C170A,  pCMV/CD63-C177A,  pCMV/CD63-
C191A and pCMV/CD63-ΔLEL were tagged with the sequence for one fluorescent 
protein each, either with mCherry or YFP (Yellow fluorescent protein). Therefore the 
five constructs, the already existing pCMV/CD63-YFP, and the pCMV/CD63-mCherry 
vectors were transformed into ER 9295. The process was the same like the one with 
the chemically competent cells, except for not plating the cells but directly culturing 
them in a 50 ml Kanamycin containing TB-medium as overnight culture. The following 
day  the  cultures  were  miniprepped  to  extract  the  plasmids  and  the  DNA 
concentration was measured. All constructs were then digested with the restriction 
enzymes ApaI and XhoI (NewEngland BioLabs®) for 6 hours at 25°C and 6 hours at 
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37°C. The restricted DNA was then resolved by agarose gel electrophoresis. The 
recombinant plasmids and the YFP and mCherry inserts were cleaned up with a gel 
extraction kit. Overall ten ligations were prepared. Each construct was once ligated 
with YFP, once with mCherry and then transformed into chemically competent cells. 
Subsequent to the amplification, the plasmids were extracted from the bacteria and 
then once again restricted by a control digest with HindIII and MfeI (ThermoScientific; 
60 minutes, 37°C). The cloning was successful if the following gel electrophoresis 
showed a 5000 bp and a 1090 bp band.
The recombinant  pCMV/CD63-ΔLEL-mCherry was further  used as  template  for  a 
series of experiments, generating CD63 hybrid molecules. Instead of just 4 glycines, 
as in the case of the LEL deletion, either a part of the HIV gp41, the gp 120 V3 or the  
fluorescent  protein  YFP  were  additionally  inserted.  The  primers  4A3/gp41  for, 
4A3/gp41 rev, 4A3/V3gp120 for and 4A3/V3gp120 rev (table 2) were used together 
with the HIV-iGFP as template. The primers 4A3/YFP for and 4A3/YFP rev were used 
with pCMV/CD63-YFP as template. The amplification was done as described before 
and the fragments, as well as the vector  pCMV/CD63-ΔLEL-mCherry were restricted 
with EcoRI and EcoRV at 37°C for 5 hours. The fragments and the vector were then 
ligated.
2.2.7. Transfection
2.2.7.1. Calcium phosphate transfection
HEK293T or TZM-bl cells growing in culture bottles were split in the stage of growth. 
For this purpose the cells were washed twice with PBS and then trypsinated through 
incubation with trypsin at 37°C and 5% CO2 atmosphere. After 10 minutes the cell 
suspension was buffered with DMEM-complete and then centrifuged (4 minutes, 800 
rpm). The supernatant was discarded, the cells resuspended and then diluted with 
DMEM-complete in a 1:10 ratio. Afterwards the cells were cultured in either 6 well  
plates, ibidi 8 well plates, 24 well plates or 96 well plates (TZM-bl). Each well of the 6  
well plates was filled with 3 ml of the prepared cell suspension, the 24 well plates  
with 500 ml each and the 96 well  plates with 170 µl each. The plates were then 
stored in the incubator (37°C; 5% CO2) for at least 24 hours, and grown until they 
were of sufficient size. The transfection media with the plasmid-DNA was then mixed 
as shown in table 8. The medium was carefully removed and replaced with fresh 
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DMEM-serum free, before the transfection medium was added to the cells dropwise. 
In case of co-transfection the amount of DNA was doubled due to the input of two 
different plasmids.
Table 8:  Calcium phosphate transfection,  amounts of  buffer,  CaCl2  and DNA for  different 
surface areas
Format Culture media Transfection 
media
1x HBS 2,5 M CaCl2 Total DNA
6 well 2 ml 1,4 ml 86 µl 5,1 µl 5,1 µg
8 well Ibidi 100 µl 50 µl 25 µl 3 µl 1 µg
24 well 500 µl 280 µl 18 µl 1,1 µl 1,1 µg
96 well 100 µl 70 µl 4,5 µl 0,3 µl 0,3 µg
2.2.7.2. Transiently transfection of HEK293T cells
Metafectene®PRO transfection was used for cell transfection in ibidi 8 wells. For this 
method the cells were prepared as described for the calcium phosphate transfection. 
For  each  transfection  two  Eppendorf  tubes  with  50  ml  DMEM-serum  free  were 
prepared. One was mixed with 1 µg of plasmid DNA and the second one was mixed 
with 2 µl Metafectene®PRO. Afterwards both mixtures were put together, carefully 
pipetted  up  and  down  and  incubated  at  room  temperature  for  20  minutes.  The 
mixture was then added to the cells dropwise.
2.2.7.3. Nucleofection
The nucleofection was used to transfect plasmids into Jurkat T cells. When in the 
stage of growth, the cells were centrifuged (4 minutes, 800 rpm), resuspended in 
RPMI-complete and the cell number was counted. For each 6 well 5x106 cells were 
pelleted and resuspended with 82 µl of the manufacturer's solution 1, 18 µl AmaxaTM 
transfection  reagent  and  3  µl  plasmid  DNA.  The  solution  was  mixed  thoroughly, 
transfected in the  nucleofector and fresh RPMI-serum-free was added immediately. 
After that the T cells were transferred into 6 wells and the transfection was checked 
after 24 hours in the incubator (37°C; 5% CO2).
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2.2.8. SDS-Polyacrylamide gel electrophoresis and Western blot
To check the expression of all recombinant proteins, the transfected cells were lysed 
48 hours post transfection. Once completed, the medium was carefully removed and 
the cells of each 6 well were lysed in 100 µl of Laemli buffer, using a sterile pipette tip 
to mix it thoroughly. In the next step 250 U of Benzonase® Nuclease  was added to  
reduce the viscosity of the cell lysate and remove nucleic acids. The lysated protein 
samples were loaded on a 10% TGX gel (BioRad) and separated by SDS-PAGE in 
an electrophoresis chamber, which was filled with running buffer (10 minutes 100V; 
40 minutes 200V). 
The separated Protein lysates on the SDS-PAGE were transferred onto a Immobilon-
P PVDF membrane (Milipore). All sample proteins were tagged with 0.5 µg/ml of a 
primary antibody (m-anti-mCherry or g-anti-FLAG) and the primary antibodies were 
detected with 0.125 µg/ml HRP-conjugated secondary antibodies (m-anti-HRP, r-anti-
HRP or g-anti-HRP). The proteins were then visualized with the Pierce ECL Western 
blotting substrate, according to the manufacturers instruction. Western blot images 
were acquired using the ChemoCam device with implemented contrast correction.
2.2.9. Infection assay
The  first  step  of  the  infection  assay  was  to  control  if  the  provirus  containing 
expression plasmids could be transfected successfully. For this purpose, HEK293T 
cells were transfected with either HIV-iGFP in each case with the calcium phosphate 
method.  The  transfections  was  checked  with  the  fluorescent  microscope  for  any 
visible GFP. To make sure that the fluorescent protein was attached to the actual 
virus, a correlative microscopy study was performed. Single transfected and therefore 
green fluorescent cells, were first searched with the confocal laser microscope and 
then co-localised with a scanning electron microscope. This study was performed by 
Dr. Kazimierz Madela (Robert Koch-Institut Berlin, Germany).
Once it was confirmed that the transfected cells expressed the different HIV-strains, 
HEK293T cells were cultured in 6 wells as described and then transfected using the 
calcium phosphate  transfection  method.  The  transfection  was  controlled  with  the 
fluorescent  microscope  24  hours  later.  After  48  hours  the  medium was  carefully  
removed with a pipette and then stored at -80°C until usage. The cells were covered 
with 2 ml of new DMEM-serum-free and restored to the CO2 incubator (37°C, 5% 
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CO2).  The  virus  containing  supernatants  were  collected  2,  5  and  7  days  post  
transfection. 
All supernatants were tested for actual virus and the amount of produced HIV-1 using 
a β-galactosidase assay (CPRG), as the provirus contains a β-galactosidase reporter 
gene.  TZM-bl  cells were prepared as described in  96 wells.  The cells were then 
infected with the HIV-1 containing supernatants 24 hours later. Per well 100 µl of PBS 
mixed with 0,5% Triton X-100 were added, after the medium was removed and then 
incubated for 20 minutes at room temperature. Subsequent to that, 100 µl of a CPRG 
solution (4 mg/ml in PBS) was added and then incubated for at 37°C until the colour 
changed from yellow to dark red. 
2.2.10. Control of the protein expression
All  recombinant  plasmids were transfected in  8  wells  as  described and  ,after  48 
hours, fixed for 20 min in 2% paraformaldehyde (PFA) which was solved in PBS. The 
five  mCherry  tagged  constructs pCMV/CD63-C145A,C146A-mCherry,  pCMV/CD63-
C169A,C170A-mCherry, pCMV/CD63-C177A-mCherry,pCMV/CD63-C191A-mCherry and 
pCMV/CD63-ΔLEL-mCherry  were  each  co-transfected  with  pCMV/CD63-YFP  as 
control.
The  YFP  tagged   pCMV/CD63-C145A,C146A-YFP,  pCMV/CD63-C169A,C170A-YFP, 
pCMV/CD63-C177A-YFP,  pCMV/CD63-C191A-YFP and  pCMV/CD63-ΔLEL-YFP 
constructs  were  each  co-transfected  with  pCMV/CD63-mCherry.  As  controls 
pCMV/mCherry or  pCMV/YFP were used. The hybrid molecules   pCMV/CD63-ΔLEL-
YFP-mCherry,  pCMV/CD63-ΔLEL-gp41-mCherry  and  pCMV/CD63-ΔLEL-gp120V3-
mCherry  were  co-transfected  with   pCMV/CD63-YFP. The  samples  were  then 
investigated with the confocal laser scanning microscope. 
To confirm the correct orientation of the CD63 hybrid proteins, a special study was 
performed together with Mrs. Gudrun Holland (Robert Koch-Institut Berlin, Germany). 
Using  2F5  antibodies,  anti-human-immunogold,  r-anti-GFP  and  anti-rabbit-
immunogold  (10  nm gold  particles)  the  plasma membrane surface of  transfected 
HEK293T cells was investigated with the scanning electron microscope.
30
3. Results
3.1. Site-directed mutagenesis 
The mutations used for the experiment were generated in the LEL of the tetraspanin  
CD63 as illustrated in table 10. Altogether four recombinant CD63-LEL expression 
plasmids were produced, each carrying either a single cysteine mutation,  C177A; 
C191A; or  a  double  cysteine  mutation,  C145A,C146A   and  C169A,C170A.  Each 
cysteine  was  replaced  with  an  alanin  to  prevent  a  frame  shift.  The  resulting 
constructs  are  pCMV/CD63-C145A,C146A,  pCMV/CD63-C169A,C170A,  pCMV/CD63-
C177A and pCMV/CD63-C191A. 
















                          CC          AA
3.2. Cloning
By cloning  the  two CD63 domains  TM1-3,  the  section  from the  first  to  the  third 
transmembrane  region  and  TM4,  the  fourth  transmembrane  region  encoding 
sequence,  a  recombinant  CD63 without  the LEL was generated.  The results  are 
illustrated in figure 2. Each protein includes the sequence for one fluorescent protein, 
either YFP or mCherry, which was proven by the control restriction digest with HindIII 
and MfeI. The resulting constructs are the expression plasmids  pCMV/CD63-ΔLEL-
mCherry and  pCMV/CD63-ΔLEL-YFP.
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Fig.2: Schematic figure of the cloning and the used restriction enzymes; pCMV/CD63-ΔLEL-mCherry 
and   pCMV/CD63-ΔLEL-YFP:  into  a  pCMV  vector  the  TM1-3,  then  the  TM4  fragment  and  the 
mCherry/  YFP  encoding  sequences  were  introduced;  pCMV/CD63-C145A,C146A-mCherry  and 
pCMV/CD63-C145A,C146A-YFP: after point mutations of the cysteines, sequences encoding for YFP 
or  mCherry  were  introduced,  the  same  procedure  was  used  for  the  other  three  point  mutated  
molecules
All point mutated constructs were also tagged with the fluorescent proteins for further 
experiments (see fig. 2) Either a YFP or a mCherry encoding DNA sequence was 
introduced to each recombinant CD63 construct. Hence, altogether ten recombinant 
expression  plasmids  were  produced.  Each  of  them  carries  the  sequence  for  a 
recombinant  CD63-LEL and  the  sequence  for  a  fluorescent  protein  that  made  it 
detectable with a fluorescent microscope. The resulting recombinant plasmids were 
provided a consistent nomenclature, which is illustrated in table 9.
Table 10: Nomenclature of the generated recombinant CD63-LEL constructs, starting with the 
name of the vector followed by the name of the protein, the introduced mutation and the 
fluorescent protein




pCMV/CD63-C191A-mCherry  pCMV/CD63-C191A-YFP 
pCMV/CD63-ΔLEL-mCherry  pCMV/CD63-ΔLEL-YFP
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3.3. Expression of CD63-LEL with introduced point mutations
The  CD63  wild  type  is  expressed  predominantly  on  the  surface  of  the  plasma 
membrane of cells. Therefore the recombinant CD63 proteins were first checked for 
their  expression  on  the  plasma  membrane.  The  pCMV/CD63-C177A-mCherry  is 
expressed on the surface of the cell membrane of the HEK293T cells. This follows a 
similar  pattern  to  the  wild  type  CD63  (Fig.  3,  pCMV/CD63-C177A-mCherry).  The 
mutants pCMV/CD63-C191A-mCherry and pCMV/CD63-C169A,C170A-mCherry (Fig. 3) 
also showed this pattern of expression, however just in a part of the investigated 
cells. In the other part of the HEK293T cells, the CD63 appeared to be expressed 
differently from the wild type protein. 
Fig. 3: Images were taken with the laser scanning microscope. HEK293T cells were co-transfected 
with Metafectene®PRO. Each row shows the co-transfected recombinant expression plasmid. Every 
mutant was co-transfected with pCMV/CD63-YFP as wild type. Cells were fixed with 2% PFA 48 hours 
post transfection and incubated with DAPI, to stain the cell nuclei, for 20 minutes.
This leaves pCMV/CD63-C177A as the only recombinant protein that was completely 
expressed  like  the  wild  type.  The  pCMV/CD63-C191A  and  the  pCMV/CD63-
C169A,C170A were not expressed consistently throughout the HEK293T cells. Figure 
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cell membrane,with a number remaining inside of some cells, which appeared to be 
the main phenotype of the pCMV/CD63-C145A,C146A mutants. 
Fig. 4:  Images were taken with the laser scanning microscope. HEK293T cells were co-transfected 
with Metafectene®PRO. Each row shows the co-transfected recombinant expression plasmid. When a 
YFP tagged construct was used, the mCherry tagged wildtype was co-transfected. When a mCherry 
tagged construct was used, the YFP tagged wildtype was co-transfected Cells were fixed with 2% PFA 
48 hours post transfection and incubated with DAPI, to stain the cell nuclei, for 20 minutes.
The protein expression was further investigated by using a western blot  analysis. 
This analysis showed that the recombinant proteins were found to be expressed (see 
Fig.  5).  The  western  blot  shows a  general  expression  of  the  recombinant  CD63 
proteins. In Fig. 5, the pCMV/CD63-C191A transfection was not successful,  therefore 














Fig. 5: Western blot analysis of the recombinant CD63 constructs with m-anti-mCherry and m-anti-
HRP antibodies. The native pCMV vector was used as negative control, and pCMV/CD63-mCherry 
wild type as positive control.
3.4. Expression of CD63-ΔLEL and its hybrid molecules
As the CD63-LEL had been expected to play an important role during the process of 
integrating the tetraspanin into the membrane, it seemed surprising when the CD63-
ΔLEL was expressed on the surface of the plasma membrane (Fig. 6). There were no 
differences seen between the mCherry tagged wild type CD63 and the ΔLEL variant 
of this protein. The western blot analysis confirmed the finding with showing that the 
CD63-ΔLEL was expressed (Fig. 7, pCMV/CD63-YFP + pCMV/CD63-ΔLEL-mCherry). 
Furthermore, this tetraspanin was expressed very efficiently, despite the fact that its 
largest  extracellular  region  was  deleted.  These  results  inspired  the  idea  of  my 
supervisor D. Ivanusic to use the  CD63-ΔLEL as a transport machine to express 
certain  proteins  on  the  plasma membrane  surface.  The  cloning  of  some foreign 
proteins was done as illustrated in Fig.  8.  Analysing the CD63- ΔLEL hybrid  co-
transfected HEK293T cells with the laser scanning microscope showed that even the 
recombinant hybrid molecules were expressed efficiently on the plasma membrane, 
just  as  the  wild  type  control  (Fig.  6,  pCMV/CD63-YFP +  pCMV/CD63-ΔLEL-gp41-
mCherry).
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Fig. 6: Images were taken with the laser scanning microscope. HEK293T cells were co-transfected 
with Metafectene®PRO. Each row shows the co-transfected as described on the right side. Controls in  
the  first  row,  both  wild  types  were  co-transfected;  fourth  row:  the  CD63-YFP wild  type  was  co-
transfected with a pCMV/mCherry expression vector. Cells were fixed with 2% PFA 48 hours post 
transfection and incubated with DAPI, to stain the cell nuclei, for 20 minutes.
Fig. 7: Western blot analysis of the recombinant  CD63-ΔLEL and the CD63-ΔLEL hybrid constructs 













The insertion of the foreign proteins was confirmed via gel electrophoresis with the 
control digestion as described within the methods. To make sure that the protein was 
being  expressed  on  the  cell  membrane,  co-transfected  HEK293T  cells  were 
investigated with the laser scanning microscope. But even then it remained unclear, if 
the protein folding was correct. To clarify the results, the fluorescent proteins YFP 
and CFP were introduced as illustrated in Fig. 8 and once again analysed with the 
laser scanning microscope (data not shown). These fluorescent proteins were used, 
because of their sensitivity to mis-foldings. Once the spatial  confirmation of these 
proteins  has  changed,  even  on  the  minutest  scale,  they  lose  their  fluorescent 
characteristics. However, as fluorescent proteins were detected, the right folding of 
introduced foreign proteins could be confirmed.
Fig. 8: Schematic figure of the cloning and the restriction enzymes used for the pCMV/CD63-ΔLEL-
mCherry hybrids ;  pCMV/CD63-ΔLEL-mCherry was used as vector. The fragments were introduced 
between the TM3 and the TM4, right where the LEL is supposed to be.
As it was still a possibility that the orientation of the protein within the membrane was 
not  correct,  therefore  an  orientation  study  as  mentioned  in  the  methods  was 
performed together with Mrs. Gudrun Holland (Robert Koch-Institut Berlin, Germany). 
The foreign proteins that were introduced between TM3 and TM4 were tagged with a 
first  antibody  that  was  detected  with  a  gold  particles  carrying  second  antibody. 
Afterwards the cell surface was investigated for these gold particles with the SEM. As 
the gold was detected on the cell  membrane surface,  the right  orientation of  the 
hybrid molecules could be confirmed. The results (Fig. 9) show that the protein is 
integrated  into  the  plasma  membrane  in  the  correct  orientation  and  therefore 
confirms that introducing foreign proteins into the CD63-ΔLEL does neither affect the 
protein folding nor the protein orientation.
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Fig.  9:  Images  were  taken  with  the  electron  scanning  microscope  by  Mrs.  Gudrun  Holland.  As 
antiboies were used h-2F5 and anti-human-immunogold, r-anti-GFP and anti-rabbit-immunogold. The 
little dots on the surface of  the HEK293T cells are 10 nm god particles that tag the CD63-ΔLEL hybrid 
molecules.
3.5. Infection assay
To confirm that the provirus containing expression plasmids were not just expressing 
the GFP but the actual virus, a comparative scanning electron microscope – confocal  
laser  scanning  microscope  (SEM-cLSM)  study  was  performed  together  with  Dr. 
Kazimierz  Madela  (Robert  Koch-Institut  Berlin,  Germany).  For  this  purpose, 
HEK293T cells were transfected with either HIV-iGFP and then investigated with the 
cLSM (except for the pNL4-3) for any visible GFP. Single transfected, therefore green 
fluorescent cells, were first searched for with the confocal laser microscope and then 
correlatively  localised  with  SEM (Fig.  10).  The  HIV1-iGFP  provirus  carrying 
expression plasmids were found to express successfully HIV-1, visualized in Figure 
10 and 11, where the virus is visible during the budding on the cell surface of the 






Fig. 10: Comparative SEM-cLSM study: images were taken by Dr. Kazimierz Madela (Robert Koch-
Institut Berlin, Germany). After localising the HIV1-expressing cells via GFP expression with the cLSM, 
the exact same cells were then investigated with the SEM.
Fig. 11: Comparative SEM-cLSM study: images were taken by Dr. Kazimierz Madela (Robert Koch-
Institut Berlin, Germany). In the left image HIV-1 budding structures are visualized on the surface of 
HEK293T cells.
The control of the virus amount in the supernatants was performed as described and 
the  samples  that  turned  dark  red  in  the  CPRG  were  picked.  Afterwards  is  was 
planned to  transfect  TZM-bl  cells  with  the  four  point  mutated constructs  and the 
pCMV/CD63-  ΔLEL. Following this, it was supposed to infect the transfected cells 
with the produced and for infectivity tested virus strains to analyse the impact of the 
introduced mutations on HIV-1 entry  and cell-to-cell  transfer.  Further  it  had been 
planned to reproduce this experiment with Jurkat T cells instead of HEK293T cells.  




The purpose of this study was, to investigate whether a deletion of the complete LEL,  
or one of the point mutations of the LEL´s cysteines would prevent the protein from 
being integrated into the cell membrane, as this process has not yet been unveiled. It  
was hypothesised that the CD63-LEL plays an important role during this process and 
deleting it therefore seemed to be the first logical step in the study. Furthermore, it 
was known that changing a protein this way can itself prevent the protein expression. 
Hence, it was surprising to discover that the deletion of the complete LEL did not  
affect this process of integration into the plasma membrane, whereas the cysteine 
mutations did. 
It could be shown that the exchange of disulphide bridge building cysteines inhibited 
the  protein  integration  in  three  out  of  four  cases.  This  seems  plausible,  as  the 
C145,C146,  C169,C170  and  C191,  but  not  the  C177  are  building  the  stabilising 
disulphide  bonds  (Fig.  1).  The  C145A,C146A  mutation  appeared  to  have  the 
strongest effect on inhibiting the CD63 integration. One possible explanation for this 
phenomenon is, as both cysteines are involved in forming disulphide bridges none of 
them can be build without these particular amino acids. Due to the disulphide bonds 
role in folding and stabilising the tertiary structure of proteins [42], their removal most 
likely causes a wrong folding of the LEL and following this a mis-folded or missing 
subloop. This steric change in the protein structure might be a bigger handicap during 
membrane  integration than deleting a whole domain (Fig. 12b). The C169,C170 and 
C191 mutations on the other hand, are each part of one disulphide bridge (Fig. 12a 
and Fig. 12b). Therefore, their deletion caused a partial change in the protein folding, 
which could  explain  that  the  inhibition of  membrane integration was just  partially 
found. The C177A mutation finally, did not cause a problem, as it is not involved in 
the tertiary structure stabilising disulphide bonds (Fig. 12a).
Further analysis of the constructs influence is still needed, to ascertain statistical data 
for the C191A and C169A,C170A mutation. Therefore it was planned to repeat this 
experiment more than once and to assess the number of cells with and without a 
surface expression. Unfortunately, due to strict time constraints these experiments 
could not be performed. But this is necessary to finally evaluate the inhibition in these 
cases. Altogether it can be said that the LEL is not the responsible CD63-domain that 
integrates the protein into the membrane. Nevertheless, a destabilisation of the LEL-
subloop causes steric problems that inhibit the protein integration.
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Fig. 12a: Schematic model of the changed protein folding after the introduced point mutations at the 
single cysteines (own illustration)
Fig. 12b: Schematic model of the changed protein folding after the introduced point mutations at the 
double cysteines (own illustration)
As a correct expression of the generated hybrid molecules was confirmed, the CD63-
ΔLEL construct   appears to be a sufficient transport machine to the cell membrane 
surface.  Overall,  it  has  very  efficient  expression,  even  after  introducing  foreign 
proteins,  which  could  be  used  in  the  field  of  immunisation  studies,  antibody 
production  or  other  immunological  experiments,  where  the  exposure  of  certain 
proteins on the cell surface is of interest. Another benefit of this system is that it can 
express  proteins  on  the  surface  of  mammalian  cells,  which  would  be  a  different 
starting point for immunisations for instance. 
However,  this  study  represents  only  the  beginning  in  establishing  this  system. 
Although the correct folding and orientation of the hybrid proteins could be confirmed, 
it still needs to be investigated, what proteins can be successfully introduced. 
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Regarding to the previous described findings, the size of the foreign protein might be 
a limiting factor, as some proteins could cause the same steric problems as the mis-
folded  LEL.  As  the  pCMV/CD63-ΔLEL-gp120-mCherry  expression  for  example 
appeared to be lethal for the transfected HEK293T cells, although the hybrid protein  
had been expressed, the ideal conditions for this system to work are important for  
successful experiments. Further, it would be needed to test this protein expression in 
other mammalian systems, such as Jurkat T cells or HeLa cells.
Further analysis could start with a co-transfection of the generated constructs with 
HIV1-iGFP provirus carrying expression plasmids to examine the influence of the 
LEL-mutations on the infectivity of released cell-free virus. This is conceivable as 
Krementsov  et  al.  confirmed  an  inhibited  cell-to-cell  transmission  and  decreased 
infectivity of cell free virus that was released from cells with a CD63 overexpression 
[3]. In general, all  experiments were planned to be replicated in Jurkat T cells, to 
establish the system in immune cells that have the CD4 receptor and due to the 
different natural amount of CD63 in different cell types. In the case of earlier studies  
that worked with the overexpression of CD63, different results in different cell lines 
were already revealed [3].  Infection assays with the virus containing supernatants 
should be performed in Jurkat  T cells to examine the influence of the expressed 
recombinant  proteins  on  HIV-1  entry,  as  the  process  of  CD63  incorporation  into 
virions is specifically found when they are released from T lymphocytes [32]. It was 
further  planned  to  co-culture  R5  tropic  infected  Jurkat  T  cells  with  uninfected  T 
lymphocytes.  Uninfected Jurkat  cells  could be tagged with  a cell  tracker  and the 
infection monitored 4, 8 and 24 hours post infection via flow cytometry. As an R5 
tropic strain is not able to infect Jurkat T cells, but to be transferred from cell to cell, it  
can  be  used  to  evaluate  the  rate  of  cell-to-cell  transmission  for  the  purpose  of 
investigating the influence of the CD63-LEL mutations. The CD63-ΔLEL protein is of 
great interest due to its role as protein binding region. However, although the CD63 
tetraspanin was found to be interacting with gp41 [7], Thali et al.   concluded that 
tetraspanins  do  not  generally  act  as  HIV-1  budding co-factors  [16].  Although  the 
results  gathered  during  the  course  of  this  research  project  have  showed  some 
promise of usefulness in the scientific field, in regards to the CD63's overall influence 
on cell free virus infectivity and cell-to-cell transfer in T lymphocytes, it would appear 
the current  understanding is  that  no  significant  influence can be shown [3].  This 
would suggest that, here too, no significant results are to be expected.
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